Phase 2 Study With SNF472 in Calciphylaxis Patients
NCT02790073
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
14
Enrollment
OTHER
Sponsor class
Conditions
Calciphylaxis
Calcific Uremic Arteriolopathy
Interventions
DRUG:
SNF472
Sponsor
Sanifit Therapeutics S. A.